ArticleImmunity, inflammation and disease2026
Protective Effects of Hyperoside on Type 2 Diabetes Through the Regulation of Pancreatic β-cell Function.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2D) is a prevalent chronic disease characterized by pancreatic β-cell loss induced by hyperglycemia. Effective treatments to repair β-cell damage remain unclear. Hyperoside, a flavonoid glycoside with diverse pharmacological effects, has rarely been studied in H
objectiveTo explore the protective effects of hyperoside on H
methodsRIN-m5F cells were pretreated with 0, 25, 50, 100 μM hyperoside or 5 μM ML385 (inhibitor of the Nrf2/HO-1 pathway) for 48 h, followed by 100 μmol/ml H
resultsHyperoside (0, 25, 50, 100 μM) showed no toxic side effects on RIN-m5F cells. H
conclusionHyperoside protects pancreatic β-cells against oxidative stress and apoptosis by activating the Nrf2/HO-1 pathway. It may serve as a potential therapeutic agent for preventing β-cell damage in T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.